It is becoming increasingly apparent that targeting the LPS–TLRs–MyD88-mediated inflammatory pathway by restoring dysbiotic gut microbiome activation may be a novel therapy against DKD. The gene discussed is MYD88; the disease is diabetic kidney disease.